^Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, Oosterhuis B, Bjerrum OJ, Rowland M, Garner C. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. European Journal of Pharmaceutical Sciences. May 2010, 40 (2): 125–131. PMID 20307657. doi:10.1016/j.ejps.2010.03.009.
^ 9.09.19.2fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders. Expert Opinion on Drug Metabolism & Toxicology. July 2009, 5 (7): 813–822. PMID 19545214. S2CID 19048690. doi:10.1517/17425250903044967.已忽略文本“ vauthors 周邊選擇性藥物 Smith SM, Gums JG ” (帮助)
^Bachert C. A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clinical Therapeutics. May 2009, 31 (5): 921–944. PMID 19539095. doi:10.1016/j.clinthera.2009.05.017.
^ 12.012.1Compalati E, Baena-Cagnani R, Penagos M, Badellino H, Braido F, Gómez RM, Canonica GW, Baena-Cagnani CE. Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. International Archives of Allergy and Immunology. 2011, 156 (1): 1–15. PMID 21969990. doi:10.1159/000321896.
^World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
^Welzel T, Ziesenitz VC, Seitz S, Donner B, van den Anker JN. Management of anaphylaxis and allergies in patients with long QT syndrome: A review of the current evidence. Annals of Allergy, Asthma & Immunology. November 2018, 121 (5): 545–551. PMID 30059791. doi:10.1016/j.anai.2018.07.027.
^Hampel F, Ratner P, Mansfield L, Meeves S, Liao Y, Georges G. Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Annals of Allergy, Asthma & Immunology. October 2003, 91 (4): 354–361. PMID 14582814. doi:10.1016/S1081-1206(10)61682-1.
^Grant JA, Riethuisen JM, Moulaert B, DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Annals of Allergy, Asthma & Immunology. February 2002, 88 (2): 190–197. PMID 11868924. doi:10.1016/S1081-1206(10)61995-3.
^Casale TB, Andrade C, Qu R. Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis. Allergy and Asthma Proceedings. 1999, 20 (3): 193–198. PMID 10389553. doi:10.2500/108854199778553046.
^Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. The Journal of Allergy and Clinical Immunology. November 1999, 104 (5): 927–933. PMID 10550734. doi:10.1016/s0091-6749(99)70070-9.
^Shirasaka Y, Mori T, Murata Y, Nakanishi T, Tamai I. Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1. Pharmaceutical Research. August 2014, 31 (8): 2035–2043. PMID 24549825. S2CID 17532347. doi:10.1007/s11095-014-1305-7.
^Shehnaz H, Haider A, Arayne MS, Sultana N. Carboxyterfenadine antacid interaction monitoring by UV spectrophotometry and RP-HPLC techniques. Arabian Journal of Chemistry. Nov 2014, 7 (5): 839–845. doi:10.1016/j.arabjc.2013.01.011.